Chemical and technological delivery systems for idebenone: A review of literature production

Expert Opinion on Drug Delivery

Volumn 9, Issue 11, 2012, Pages 1377-1392

  Carbone, Claudia ^a   Pignatello, Rosario ^a   Musumeci, Teresa ^a   Puglisi, Giovanni ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antioxidant activity; Cyclodextrins; Drug delivery systems; Lipoamino acids; Liposomes; Microemulsions; Nanoparticles; Prodrugs; SLN; Solid lipid nanoparticles

Indexed keywords

BETA CYCLODEXTRIN; CYCLODEXTRIN; IDEBENONE; LACTATE DEHYDROGENASE; LIPID; LIPOSOME; NANOPARTICLE; POLYMER; PRODRUG; REACTIVE OXYGEN METABOLITE;

ARTICLE; ASTROCYTE; DIARRHEA; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DYSPEPSIA; FIBROBLAST; HUMAN; MICROEMULSION; NAUSEA; NONHUMAN;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; NANOPARTICLES; POLYMERS; PRODRUGS; SOLUBILITY; UBIQUINONE;

EID: 84867823334     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.724396     Document Type: Article

References (60)

1. Sugiyama Y, Fujita T, Matsumoto M, et al. Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J. Pharmacobiodyn 1985;8:1006-17 (Pubitemid 16190424)
2. James AM, Cochemé HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J. Biol. Chem 2005;280:21295-312 (Pubitemid 40805692)
3. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochem Biophys Acta 1995;1271:195-204
4. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem 2011;18:3871-88
5. Rauchova H, Vrbacky M, Bergamini C, et al. Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone. Biochem Biophys ResCommun 2006;339:362-6 (Pubitemid 41697558)
6. Suno M, Nagaoka A. Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinate. Arch Gerontol Geriatr 1989;8:291-7 (Pubitemid 19125295)
7. Jauslin ML, Wirth T, Meier T, Schoumacher F. A cellular model for Friedreich ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet 2002;11:3055-63 (Pubitemid 35414819)
8. Becker C, Bray-French K, Drewe J. Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab. Toxicol 2010;6:1437-44
9. EMEA/387246/2009 CHMP Assessment Report for Sovrima. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/000908/WC500070576.pdf [Last Accessed 31 July 2012]
10. Haefeli RH, Erb M, Gemperli AC, et al. NQO1-Dependent Redox Cycling of Idebenone: effects on Cellular Redox Potential and Energy Levels. PLoS One 2011;6:e17963
11. Lagedrost SJ, Sutton MJ, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-moth phase III study (IONIA). Am Heart J 2011;161:639-45
12. Meier T, Buyse G. Idebenone: An emerging therapy for Friedreich ataxia. J. Neurol 2009;256:25-30
13. Giorgio V, Petronilli V, Ghelli A, et al. The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta 2012;1817:363-9
14. Suno M, Nagaoka A. Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Commun 1984;125:1046-52 (Pubitemid 15152897)
15. Meldrum BS. Glutamate as a neurotrasmitter in the brain: review of physiology and pathology. J Nutr 2000;130:1007S-15S (Pubitemid 30173635)
16. Mancuso M, Orsucci D, Choub A, Siciliano G. Current and emerging treatment options in the management of Friedreich ataxia. Neuropsychiatr Dis Treat 2010;6:491-9
17. Seznec H, Simon D, Monassier L, et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Gen 2004;13:1017-24 (Pubitemid 38702188)
18. Rustin P, Von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyophathy in Friedreich's ataxia: A preliminary study. Lancet 1999;354:477-9 (Pubitemid 29368927)
19. Shulz JB, Dehmer T, Schools L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000;55:1719-21
20. Idebenone Friedreich Ataxia. ClinicalTrials gov A service of the U S National Institutes of Health. 2012.Available from: http://www. clinicaltrials gov/ct2/results? term=idebenone+Friedreich+ataxia+ [Last accessed 21 May 2012]
21. Buyse GM, Goemans N, van den Hauwe M, et al. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul Disord 2011;21:396-405
22. Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy (DELPHI). 2012.ClinicalTrials gov A service of the U S National Institutes of Health. Available from: http://www.clinicaltrials gov/ct2/results?term=idebenone +Duchenne+muscular+dystrophy+ [Last accessed 21 May 2012]
23. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011;134:2677-86
24. Carelli V, La Morgia C, Valentino ML, et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011;134:e188
25. Sabet-Peyman EJ, Khaderi KR, Sadun AA. Is leber hereditary optic neuropathy treatable? Encouraging results with idebenone in both prospective and retrospective trials and an illustrative case. J Neuroophtalmol 2012;32:54-7
26. Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophtalmol 2000;20:166-70
27. Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes (MELAS). ClinicalTrials gov A service of the U S National Institutes of Health. 2012.Available from: http://www. clinicaltrials.gov/ct2/show/NCT00887562?term=idebenone +MELAS&rank=1[Last accessed 21 May 2012]
28. Douglas KS. Treatment of mitochondrial electron transport chain disorders: A review of clinical trials over the past decade. Mol Genet Metab 2010;99:246-55
29. Lekoubou A, Kouamé-Assouan AE, Cho TH, et al. Effect of long-term oral treatment with L-arginine and idebenone on the prevention of stroke-like episodes in an adult MELAS patient. Rev Neurol (Paris) 2011;167:852-5
30. Orsucci D, Mancuso M, Ienco EC, et al. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr Med Chem 2011;18:4053-64
31. Haginoya K, Miyabayashi S, Kikuchi M, et al. Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: A long-term follow-up study. J Neurol Sci 2009;278:112-14
32. Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS). ClinicalTrials gov A service of the U S National Institutes of Health. 2012.Available from: http://www. clinicaltrials gov/ct2/show/NCT00950248?term=idebenone+primary +progressive+multiple+sclerosis&rank=1[Last accessed 21 May 2012]
33. Mc Daniel DH, Neudecker BA, Di Nardo JC, et al. Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone. J Cosmet Dermatol 2005;4:167-73
34. Ventura CA, Fresta M, Giovinazzo C, Puglisi G. Solid state characterization and in solution studies of idebenone-b-cyclodextrin inclusion complex. Acta Technologiae et Legis Medicamenti 1995;VI:55-66
35. Puglisi G, Ventura CA, Fresta M. Preparation and physico-chemical study of inclusion complexes between idebenone and modified b-cyclodextrins. J Inclusion Phenom Mol Recognit Chem 1996;24:193-210 (Pubitemid 126652456)
36. Cannava C, Crupi V, Guardo M, et al. Phase solubility and FTIR-ART studies of idebenone/sulfobutylether b-cyclodextrin inclusion complex. J Inclusion Phenom Mol Recognit Chem. In press 2012
37. Muscoli C, Fresta M, Cardile V, et al. Ethanol-induced injury in rat primary cortical astrocytes involves oxidative stress: effect of idebenone. Neurosci Lett 2002;329:21-4
38. Paolino D, Iannone M, Cardile V, et al. Tolerability and improved protective action of idebenone-loaded pegylated liposomes on ethanol-induced injury in primary cortical astrocytes. J Pharm Sci 2004;93:1815-27 (Pubitemid 38823707)
39. Fresta M, Ventura CA, Mezzasalma E, Puglisi G. A calorimetric study on the idebenone-phospholipid membrane interaction. Int J Pharm 1998;163:133-43 (Pubitemid 28162627)
40. Pignatello R, Musumeci T, Basile L, et al. Biomembrane models and drug-biomembrane interaction studies: involvement in drug design and development. J Pharm Bioall Sci 2011;3:4-14
41. Montenegro L, Carbone C, Condorelli G, et al. Effect of oil phase lipophilicity on in vitro drug release from O/W microemulsions with low surfactant content. Drug Dev Ind Pharm 2006;32:539-48 (Pubitemid 43982404)
42. Schmalfub U, Neubert R, Wohlrab W. Modification of drug penetration into human skin using microemulsions. J Control Release 1997;46:279-85 (Pubitemid 27132852)
43. Gasco MR. Microemulsions in the pharmaceutical filed: Perspective and application. In: Solans C, Kunieda H, editors. Industrial applications of microemulsions. Marcel Dekker; New York: 1997. p. 97-122
44. Kim HJ, Yoon KA, Hahn M, et al. Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. Drug Dev Ind Pharm 2000;26:523-9 (Pubitemid 30225630)
45. Palumbo M, Russo A, Cardile V, et al. Improved antioxidant effect of idebenone-loaded polyethyl-2-cyanoacrylate nanocapsules tested on human fibroblasts. Pharm Res 2002;19:71-8 (Pubitemid 34075109)
46. de Amorim CM, Couto AG, Netz DJA, et al. Antioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosan. Nanomedicine 2010;6:745-52
47. Yang CH, Huang KS, Lin YC. Using a cross-flow microfluidic chip and external crosslinking reaction for monodisperse TPP-chitosan microparticle. Sens Actuators B 2007;12:510-16
48. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77 (Pubitemid 30326695)
49. Pignatello R, Ricupero N, Bucolo C, et al. Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech 2006;7:E27
50. Stancampiano AH, Acquaviva R, Campisi A, et al. Technological and biological characterization of idebenone-loaded solid lipid nanoparticles prepared by a modified solvent injection technique. J Biomed Nanotechnol 2006;2:253-60
51. Montenegro L, Campisi A, Sarpietro MG, et al. In vitro evaluation of idebenone-loaded solid lipid nannoparticles for drug delivery to the brain. Drug Dev Ind Pharm 2011;37:737-46
52. Montenegro L, Trapani A, Latrofa A, Puglisi G. In vitro evaluation on a model of blood brain barrier of idebenone-loaded solid lipid nanoparticles. J Nanosci Nanotechnol 2012;12:330-7
53. Montenegro L, Sinico C, Castangia I, et al. Idebenone-loaded solid lipid nanoparticles for drug delivery to the skin: in vitro evaluation. Int J Pharm 2012;434:169-74
54. Teeranachaideekul V, Souto EB, Junyaprasert VB, Muller RH. Cetyl palmitate-based NLC for topical delivery os Coenzyme Q10 - development, physicochemical characterization and in vitro release study. Eur J Pharm Biopharm 2007;67:141-8 (Pubitemid 46991336)
55. Li B, Ge ZQ. Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone. AAPS PharmSciTech 2012;13:276-83; (2006) 299:626-35
56. Toth I. A novel chemical approach to drug delivery: lipidic amino acid conjugates. J Drug Target 1994;2:217-39 (Pubitemid 24310625)
57. Pignatello R, Puleo A, Acquaviva R, et al. Lipophilic conjugates of idebenone with short and medium alkylamino acids: synthesis and antioxidant activity. J Drug Del Sci Tech 2004;14:181-6 (Pubitemid 38797164)
58. Puleo A, Niemi R, Jarvinen T, et al. Chemical and enzymatic stability evaluation of lipoamino acid esters of idebenone. Eur J Pharm Biopharm 2004;57:343-6 (Pubitemid 38283713)
59. Pignatello R, Intravaia VD, Puglisi G. A calorimetric evaluation of the interaction of amphiphilic prodrugs of idebenone with a biomembrane model. J Colloid Interface Sci 2006;299:626-35 (Pubitemid 43795806)
60. Pignatello R, Acquaviva R, Campisi A, et al. Effects of liposomal encapsulation on the antioxidant activity of lipophilic prodrugs of idebenone. J Liposome Res 2011;21:46-54